Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives

Kaitlind C. Howard; Sylvie Garneau-Tsodikova

doi:10.1021/acs.jmedchem.2c01471

Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives

Kaitlind C. Howard, Sylvie Garneau-Tsodikova

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Periodontal diseases are inflammatory diseases triggered by pathogenic oral bacterial species, such as Porphyromonas gingivalis. Zafirlukast (ZAF) has displayed antibacterial activity against P. gingivalis. Herein, we report the design, synthesis, and selective antibacterial activity of 14 novel third-generation ZAF derivatives. Two second-generation ZAF derivatives were tested as they were not previously tested against P. gingivalis ATCC 33277. Most third-generation derivatives displayed superior/selective antibacterial activity against P. gingivalis compared to ZAF and its second-generation derivatives. The compounds displayed bactericidal activity against P. gingivalis, inhibited biofilm growth, displayed no hemolytic activity, and displayed less cytotoxicity against mammalian cells than ZAF. The superior/selective antibacterial activity of ZAF derivatives against P. gingivalis, increased safety profile, and inhibition of biofilm growth compared to ZAF indicate that the compounds, especially 21a, 21b, and 24g, show promise as antibacterial agents for future studies to test their potential for preventing and treating P. gingivalis-induced periodontal diseases.

Original language	English
Pages (from-to)	14938-14956
Number of pages	19
Journal	Journal of Medicinal Chemistry
Volume	65
Issue number	21
DOIs	https://doi.org/10.1021/acs.jmedchem.2c01471
State	Published - Nov 10 2022

Bibliographical note

Funding Information:
This work was supported by a National Institutes of Health (NIH) F31 fellowship DEO29661 (to K.C.H.). The authors thank the UK PharmNMR Center (in the College of Pharmacy) for NMR support, Dr. Octavio A. Gonzalez (University of Kentucky) for discussions as well as help with the reagents and use of instruments, Dr. Nishad Thamban Chandrika for his help with HPLC and HRMS, and Dr. J. G. Rheinwald (Harvard Medical School) for sharing the oral keratinocyte cell line OKF6/hTERT (OKF6).

Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1021/acs.jmedchem.2c01471

Cite this

@article{e073bedd526b46ed970924d3a90d3458,

title = "Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives",

abstract = "Periodontal diseases are inflammatory diseases triggered by pathogenic oral bacterial species, such as Porphyromonas gingivalis. Zafirlukast (ZAF) has displayed antibacterial activity against P. gingivalis. Herein, we report the design, synthesis, and selective antibacterial activity of 14 novel third-generation ZAF derivatives. Two second-generation ZAF derivatives were tested as they were not previously tested against P. gingivalis ATCC 33277. Most third-generation derivatives displayed superior/selective antibacterial activity against P. gingivalis compared to ZAF and its second-generation derivatives. The compounds displayed bactericidal activity against P. gingivalis, inhibited biofilm growth, displayed no hemolytic activity, and displayed less cytotoxicity against mammalian cells than ZAF. The superior/selective antibacterial activity of ZAF derivatives against P. gingivalis, increased safety profile, and inhibition of biofilm growth compared to ZAF indicate that the compounds, especially 21a, 21b, and 24g, show promise as antibacterial agents for future studies to test their potential for preventing and treating P. gingivalis-induced periodontal diseases.",

author = "Howard, {Kaitlind C.} and Sylvie Garneau-Tsodikova",

note = "Funding Information: This work was supported by a National Institutes of Health (NIH) F31 fellowship DEO29661 (to K.C.H.). The authors thank the UK PharmNMR Center (in the College of Pharmacy) for NMR support, Dr. Octavio A. Gonzalez (University of Kentucky) for discussions as well as help with the reagents and use of instruments, Dr. Nishad Thamban Chandrika for his help with HPLC and HRMS, and Dr. J. G. Rheinwald (Harvard Medical School) for sharing the oral keratinocyte cell line OKF6/hTERT (OKF6). Publisher Copyright: {\textcopyright} 2022 American Chemical Society. All rights reserved.",

year = "2022",

month = nov,

day = "10",

doi = "10.1021/acs.jmedchem.2c01471",

language = "English",

volume = "65",

pages = "14938--14956",

number = "21",

}

TY - JOUR

T1 - Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives

AU - Howard, Kaitlind C.

AU - Garneau-Tsodikova, Sylvie

N1 - Funding Information: This work was supported by a National Institutes of Health (NIH) F31 fellowship DEO29661 (to K.C.H.). The authors thank the UK PharmNMR Center (in the College of Pharmacy) for NMR support, Dr. Octavio A. Gonzalez (University of Kentucky) for discussions as well as help with the reagents and use of instruments, Dr. Nishad Thamban Chandrika for his help with HPLC and HRMS, and Dr. J. G. Rheinwald (Harvard Medical School) for sharing the oral keratinocyte cell line OKF6/hTERT (OKF6). Publisher Copyright: © 2022 American Chemical Society. All rights reserved.

PY - 2022/11/10

Y1 - 2022/11/10

N2 - Periodontal diseases are inflammatory diseases triggered by pathogenic oral bacterial species, such as Porphyromonas gingivalis. Zafirlukast (ZAF) has displayed antibacterial activity against P. gingivalis. Herein, we report the design, synthesis, and selective antibacterial activity of 14 novel third-generation ZAF derivatives. Two second-generation ZAF derivatives were tested as they were not previously tested against P. gingivalis ATCC 33277. Most third-generation derivatives displayed superior/selective antibacterial activity against P. gingivalis compared to ZAF and its second-generation derivatives. The compounds displayed bactericidal activity against P. gingivalis, inhibited biofilm growth, displayed no hemolytic activity, and displayed less cytotoxicity against mammalian cells than ZAF. The superior/selective antibacterial activity of ZAF derivatives against P. gingivalis, increased safety profile, and inhibition of biofilm growth compared to ZAF indicate that the compounds, especially 21a, 21b, and 24g, show promise as antibacterial agents for future studies to test their potential for preventing and treating P. gingivalis-induced periodontal diseases.

AB - Periodontal diseases are inflammatory diseases triggered by pathogenic oral bacterial species, such as Porphyromonas gingivalis. Zafirlukast (ZAF) has displayed antibacterial activity against P. gingivalis. Herein, we report the design, synthesis, and selective antibacterial activity of 14 novel third-generation ZAF derivatives. Two second-generation ZAF derivatives were tested as they were not previously tested against P. gingivalis ATCC 33277. Most third-generation derivatives displayed superior/selective antibacterial activity against P. gingivalis compared to ZAF and its second-generation derivatives. The compounds displayed bactericidal activity against P. gingivalis, inhibited biofilm growth, displayed no hemolytic activity, and displayed less cytotoxicity against mammalian cells than ZAF. The superior/selective antibacterial activity of ZAF derivatives against P. gingivalis, increased safety profile, and inhibition of biofilm growth compared to ZAF indicate that the compounds, especially 21a, 21b, and 24g, show promise as antibacterial agents for future studies to test their potential for preventing and treating P. gingivalis-induced periodontal diseases.

UR - http://www.scopus.com/inward/record.url?scp=85140828111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140828111&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.2c01471

DO - 10.1021/acs.jmedchem.2c01471

M3 - Article

C2 - 36273428

AN - SCOPUS:85140828111

SN - 0022-2623

VL - 65

SP - 14938

EP - 14956

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 21

ER -

Selective Inhibition of the Periodontal Pathogen Porphyromonas gingivalis by Third-Generation Zafirlukast Derivatives

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this